Braveheart Bio (NASDAQ:BRVE) Director Christopher Viehbacher Purchases 83,333 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Christopher Viehbacher acquired 83,333 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the transaction, the director directly owned 609,519 shares of the company’s stock, valued at approximately $10,971,342. The trade was a 15.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Braveheart Bio Stock Performance

Shares of Braveheart Bio stock traded up $0.20 on Friday, hitting $30.00. The stock had a trading volume of 565,846 shares. Braveheart Bio, Inc. has a one year low of $28.47 and a one year high of $32.00.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.